Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab for Unresectable or Metastatic Basal Cell Carcinoma
NCT02690948Phase 2Completed
- Start
- Feb 2016
- Primary completion
- Nov 2017
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in basal cell carcinoma (BCC). Started Feb 2016; status: completed.
02
Drugs
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT02690948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02690948.